ArticleAmerican journal of translational research2026
FAM19A5 is an independent prognostic biomarker in thyroid cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Can Adipokine FAM19A5 Be a Biomarker of Metabolic Disorders?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesFamily with sequence similarity 19 member A5 (FAM19A5), also known as TAFA chemokine-like family member 5 (TAFA5), has been implicated in tumorigenesis. This study aimed to investigate the role of FAM19A5 in thyroid cancer (TC) using bioinformatics analysis and
methodsRNA sequencing (RNA-seq) data and clinicopathologic characteristics of 513 patients with papillary thyroid cancer (PTC) were retrieved from the Cancer Genome Atlas (TCGA) database and re-analyzed. The diagnostic performance of FAM19A5 was evaluated using receiver operating characteristic (ROC) curve analysis. The Kaplan-Meier method was used to analyze overall survival (OS) and disease-specific survival (DSS). Cox regression analysis was performed to identify independent risk factors for PTC. Gene set enrichment analysis (GSEA) was applied to explore signaling pathways associated with FAM19A5. The mRNA expression of FAM19A5 was detected by quantitative real-time PCR (RT-qPCR). Cell proliferation, migration, and invasion were assessed using colony formation, wound healing, and Transwell assays, respectively. Protein expression of FAM19A5 and nuclear factor kappa B (NF-κB) pathway-related proteins was detected by Western blot.
resultsFAM19A5 expression was significantly upregulated in TC tissues and cells. Elevated FAM19A5 expression was correlated with advanced T stage, lymph-node metastasis, and poorer OS and DSS. GSEA showed enrichment of NF-κB signaling pathways in tumors with high FAM19A5 high-expression. FAM19A5 knockdown significantly inhibited TC cell proliferation, migration, and invasion. Furthermore, treatment with tumor necrosis factor alpha (TNF-α), an activator of NF-κB, reversed the inhibitory effects induced by FAM19A5 knockdown.
conclusionsFAM19A5 is an independent predictor of poor prognosis in TC and may serve as a potential therapeutic target. Mechanistically, FAM19A5 knockdown suppresses TC cell proliferation, migration, and invasion, potentially through modulation of the NF-κB pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.